A team of scientists who a few years ago identified a major pathway that leads to brain cell death in mice, have now found two drugs that block the pathway and prevent neurodegeneration. The drugs caused minimal side effects in the mice and one is already licensed for use in humans, so is ready for clinical trials.
The University of Cambridge has been announced as one of the centres that will form the UK Dementia Research Institute (UK DRI) alongside Cardiff University, the University of Edinburgh, Imperial College London and King’s College London.
Public attitudes towards end-of-life care in progressive neurological illness are conflicted, study reveals05 Apr 2017
Public attitudes in UK and USA reveal support both for life-sustaining interventions and for measures to enable peaceful death in progressive neurological illness such as dementia, according to a survey carried out by researchers at the University of Cambridge.
It's over a hundred years since the first case of Alzheimer’s disease was diagnosed. Since then we’ve learned a great deal about the protein ‘tangles’ and ‘plaques’ that cause the disease. How close are we to having effective treatments – and could we even prevent dementia from occurring in the first place?
A specific gene expression pattern maps out which parts of the brain are most vulnerable to Alzheimer’s disease, decades before symptoms appear, and helps define the molecular origins of the disease.
The UK has seen a 20% fall in the incidence of dementia over the past two decades, according to new research from England, led by the University of Cambridge, leading to an estimated 40,000 fewer cases of dementia than previously predicted. However, the study, published today in Nature Communications, suggests that the dramatic change has been observed mainly in men.
An approved anti-cancer drug successfully targets the first step in the toxic chain reaction that leads to Alzheimer’s disease, suggesting that treatments may be found to lower the risk of developing the neurodegenerative condition.
Scientists at the University of Cambridge have identified a new property of essential proteins which, when it malfunctions, can cause the build up, or ‘aggregation’, of misshaped proteins and lead to serious diseases.
The number of people with dementia – both new cases and total numbers with the disease – appears to be stabilising in some Western European countries despite populations ageing, in direct contrast to the ‘dementia epidemic’ reported in some recent studies. Professor Carol Brayne and Yu-tzu Wu from the Cambridge Institute of Public Health explore what this means.
Restoring the low levels of the chemical serotonin may help improve brain function and reduce impulsivity in some dementia patients, according to Cambridge researchers. A study published in the July edition of the journal Brain suggests a potential new treatment for people affected by frontotemporal dementia.